Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Philogen to present at the CEO Roundtable Zoom Session organised by Goldman Sachs in June, 2021

Philogen announces its participation at the CEO Roundtable Zoom Session organised by Goldman Sachs from June 8 to 29, 2021. Co-founder, CEO and CSO, Prof. Dario Neri...

Philogen to participate at the BIO Digital 2021 on June 14-18, 2021

Philogen participates at the BIO Digital 2021, the international partnering event in the life science and pharma industry, on June 14-18, 2021. Please meet with us in...

Philogen to organise a non-deal Roadshow with Investors on July 5-7, 2021

Philogen announces the organization of a non-deal Roadshow with Investors on July 5-7, 2021. The event will be organised together with Mediobanca, Goldman Sachs and...

Philogen to attend the 11th Post-Chicago Meeting on Melanoma / Skin Cancer on July 8-9, 2021

Philogen announces its participation at the virtual 11th Post-Chicago Meeting on Melanoma / Skin Cancer organised by the European Association of Dermatology-Oncology...

Philogen to present at the 5th Annual EU Investor Tour on July 13-14, 2021

Philogen is attending the 5th Annual EU Summer Investor Virtual Tour organized by Solebury Trout & Venrock on July 13-14, 2021. Co-founder, CEO and CSO, Prof. Dario...

Philogen S.p.A. announces its maiden First Quarter 2021 Results on Wednesday 12th May 2021

A virtual briefing was hosted for sell-side analysts at 9:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021. Please find the link to the recording...

Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress

  COMUNICATO STAMPA 05-12-2021   PRESS RELEASE - 2021-05-12

Philogen will be attending the PEGS Boston Virtual Summit

Philogen will be attending the PEGS Boston Virtual Summit from May 11th to 13th, 2021. Alessandra Villa, Head of Antibody Research will give a lecture with the...

Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS

Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs. OncoFAP-based molecules are currently being developed for the...

Philogen announces its intention to float on the Mercato Telematico Azionario organised and managed by Borsa Italiana S.P.A


Learn about our strategy


Learn more about our pipeline


Look at open positions